Deepali Gupta, MD
Interventional Pain Medicine · Brooklyn, NYNPI 1689802464
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,516 of the $4,756 with a category attached, or 73.9%. 18 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 30.9% of the total. Reporting peaked in 2021 at $1,760 and has fallen 68.9% since, to $547 in 2025.
Across 249 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Pfizer$725
- Teva Pharmaceuticals USA, Inc.$421
- Lilly USA, LLC$399
- Biohaven Pharmaceutical Holding Company Ltd.$123
- plus $548 from 12 others
What the payments were for
- Consulting fees$1,20025%
- Travel & lodging$401%
- Food & beverage$3,51674%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 10 | $1,470 |
| AbbVie(2 entities) | 84 | $1,070 |
| Pfizer | 63 | $725 |
| Teva Pharmaceuticals USA, Inc. | 24 | $421 |
| Lilly USA, LLC | 28 | $399 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $123 |
| Novartis | 7 | $109 |
| Boston Scientific | 5 | $103 |
| Abbott | 2 | $75 |
| Amgen | 5 | $72 |
| Si-bone, Inc. | 1 | $33 |
| Nevro Corp. | 1 | $30 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Bioventus LLC | 1 | $27 |
| Nalu Medical, Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Merz Pharmaceuticals, LLC | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,344
How this compares
$4,756 in reported general payments places this provider in the 55th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 28 | $560 |
| Gabapentin | 14 | $174 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Brooklyn
- Leonid ReyfmanBrooklyn$16K
- Dmitriy DvoskinBrooklyn$6K
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Hemant KaliaRochester$179K
- Martin FerrilloAlbany$164K
- George ChaseKew Gardens$102K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.